
AngioDynamics (ANGO) Stock Forecast & Price Target
AngioDynamics (ANGO) Analyst Ratings
Bulls say
AngioDynamics Inc. is experiencing growth in its customer base within both the outpatient behavioral health (OBL) and hospital settings, which contributes to an increase in average selling price (ASP). The company's gross margin improvement efforts, set for completion by January 2026, are expected to enhance profitability, supported by a favorable revenue mix that leans towards higher Med-Tech revenues, currently reflecting a gross margin of 52.5%. Furthermore, management anticipates ongoing growth driven by new customer acquisitions, increased utilization in existing accounts, and successful pricing strategies for its product offerings.
Bears say
AngioDynamics Inc. faces a challenging outlook due to expected tariff headwinds of $4 million to $6 million affecting its financial guidance, which could compress profit margins. Additionally, management anticipates increased pressure on inventory in the second half of fiscal year 2026 due to rising raw material prices, potentially impacting operational efficiency and cost management. While recent performance in capital sales indicates a favorable demand trend, the reliance on these sales raises concerns about the sustainability of revenues, particularly for disposable products moving forward.
This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.
AngioDynamics (ANGO) Analyst Forecast & Price Prediction
Start investing in AngioDynamics (ANGO)
Order type
Buy in
Order amount
Est. shares
0 shares